Clinical trial
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and…
NCT00114179 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00114179 |
|---|---|
| Title | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery |
| Official title | A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | NRG Oncology |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | capecitabine, radiation therapy, bevacizumab, therapeutic conventional surgery, gemcitabine hydrochloride |
| Enrollment | 82 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jun 14, 2005 |
| Last update posted | Oct 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: